Executive Summary: Key Legal and Evidentiary Issues

• The case involved a dispute over whether a 9% insurance premium tax applied to a specific individual insurance contract offered by Medavie Inc.

• Revenu Québec reassessed Medavie for not collecting the tax on contracts that excluded pharmaceutical coverage.

• Interpretation of sections 15.1, 16, and 42.2 of the Loi sur l’assurance médicaments (LAMED) was central to determining tax applicability.

• Medavie argued that the contract in question was not subject to the tax because it did not provide drug coverage.

• The court focused on legislative intent and public policy objectives embedded in Québec’s mandatory drug insurance scheme.

• It was ultimately found that Medavie’s separation of coverages circumvented the law’s design and triggered tax liability.

Background and contractual context

Medavie Inc., an insurer licensed in Québec, entered into two separate insurance agreements with the Barreau du Québec. The first contract (contract no. 1) offered accident, illness, and disability coverage, but notably excluded pharmaceutical benefits. The second contract (contract no. 2) provided pharmaceutical and drug coverage without including accident or disability insurance. Both contracts were made available to members of the Barreau, but they were structured as distinct products, and Medavie did not charge the 9% tax on insurance premiums (TPA) for contract no. 1.

Tax reassessment and Medavie’s challenge

Revenu Québec issued a reassessment to Medavie in 2022 for failing to collect the TPA on contract no. 1 for the 2018–2020 period. The amount assessed was $111,919.39. Medavie contested the reassessment, arguing that since contract no. 1 lacked drug coverage, it did not fall under the provisions of the Loi sur l’assurance médicaments (LAMED), specifically article 42.2, and was thus not subject to the insurance premium tax under article 515.1 of the Loi sur la taxe de vente du Québec (LTVQ).

Core legal question

The key issue before the Cour du Québec was whether a contract that excludes drug coverage but includes accident, illness, and disability guarantees qualifies under the LAMED as a contract subject to the TPA. This required a detailed interpretation of LAMED articles 15.1, 16, and 42.2 and related provisions under the LTVQ. Revenu Québec argued that the contract met all the criteria to be considered equivalent to a collective contract, thereby triggering the tax requirement—even in the absence of drug coverage.

Legal interpretation and statutory purpose

The court emphasized the importance of interpreting LAMED in light of its social welfare purpose. Québec's pharmaceutical insurance regime, as defined under LAMED, is a public policy tool designed to ensure equitable access to drug coverage. The law mandates that private insurers offering collective-type insurance must include at least the same level of pharmaceutical coverage as the public plan. The court examined legislative debates and policy notes indicating that splitting coverage across two contracts—one for drugs and one for other health needs—contravenes the scheme’s intent. The goal is to avoid individuals bypassing drug coverage and falling into the public plan, which acts as a safety net only when no private options are available.

Court’s conclusion

The court ruled that contract no. 1 was subject to the 9% TPA. It determined that Medavie could not legally offer accident, illness, and disability coverage to Barreau members without incorporating pharmaceutical coverage within the same contract. Doing so allowed members to avoid private drug insurance and default into the public system, an outcome the legislation sought to prevent. The structure of the contracts was found to be inconsistent with article 42.2 LAMED and the tax obligations under the LTVQ.

Final judgment

The Cour du Québec dismissed Medavie Inc.’s application and upheld the tax assessment issued by Revenu Québec. The judge confirmed that the premiums collected under contract no. 1 were taxable and not exempt from the TPA, ordering Medavie to pay the reassessed amount, along with legal costs.